Trial Profile
Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2018
Price :
$35
*
At a glance
- Drugs Oxymetazoline (Primary)
- Indications Erythema
- Focus Therapeutic Use
- Acronyms REVEAL 2
- Sponsors Allergan
- 30 Jan 2018 Primary endpoint (Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for Rosacea Facial Redness (SSA) 5-point Scales) has been met as per the results published in the Journal of the American Academy of Dermatology
- 30 Jan 2018 Results (n=885) of pooled analysis of REVEAL 1 and REVEAL 2 trials assessing safety and efficacy published in the Journal of the American Academy of Dermatology
- 24 May 2017 Results from this and one other study (NCT02131636) assessing the Impact Assessment for Rosacea Facial Redness (IA-RFR) outcome, presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.